Ultragenyx to Participate in the Jefferies London Healthcare Conference
08 11월 2023 - 7:00AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultrarare genetic diseases, today
announced that Emil D. Kakkis, M.D., Ph.D., the company's chief
executive officer and president, will participate in a fireside
chat at the upcoming Jefferies London Healthcare Conference on
Tuesday, November 14, 2023, at 12:30 p.m. GMT.
The live and archived webcast of the panel will be accessible
from the company’s website at
https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.InvestorsJoshua Higa
ir@ultragenyx.com
MediaJeff Blake media@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024